Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

The National Health Care Institute has approved a pharmacotherapeutic report for the medicine safinamide (Xadago®). They reached the following conclusion.Based on the criteria of the Medicines Reimbursement System (GVS), safinamide can be includedin the GVS on List 1A in cluster 0N04BD AO V, with a standard dose of 75mg.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.